December 1, 2021
The Japan arm of Bristol Myers Squibb said on November 30 that it has filed a new drug application in the country for deucravacitinib for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis. Deucravacitinib is the first oral...read more